Hepatic Encephalopathy (HE) Therapeutics Market: 41% of Growth to Originate from North America | By Product (NADs, antibiotics, and others) and Geography | Market Size, Share, Outlook, and Opportunity Analysis, 2021

Request a free sample report to know exact growth variance and the YOY growth rate

Hepatic Encephalopathy (HE) Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 6.08%

Market growth 2021-2025

$ 1.00 billion

Market structure

Fragmented

YoY growth (%)

3.05

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 41%

Key consumer countries

US, UK, Germany, China, and Canada

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period,

Customization preview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Hepatic Encephalopathy (HE) Therapeutics Market 2021-2025: Segmentation

The hepatic encephalopathy (HE) therapeutics market share growth by the NAD segments will be significant during the forecast period. The NADs segment will grow moderately during the forecast period. Although rifaximin is better tolerated, NADs are preferred as the first line of therapy due to the side effects associated with antibiotics, such as alterations in gut flora. NADs are also inexpensive. Hence, the demand for NAD HE therapeutics is expected to increase during the forecast period.

  • Geography
    • North America
    • Europe
    • Asia
    • RO

41% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for hepatic encephalopathy (HE) therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.

The presence of the US, which is the largest market for pharmaceuticals in the world will facilitate the hepatic encephalopathy (HE) therapeutics market growth in North America over the forecast period.

Request for a FREE sample now! For more insights on the market share & contribution of various regions & segments

Availability of Patient-focused Programs to Assist Disease Management to Drive the Market Growth
Vendors in the market conduct several programs to help patients manage HE. For instance, Salix conducts the Hepatic Encephalopathy Living Program (HELP), which provides support to patients and their caregivers to manage HE. HELP provides a 24/7 helpline service that is managed by trained nurses to address queries and make reminder calls about medicine refills and doctor visits. Such programs improve convenience for patients, which increases adherence to therapeutics. The availability of such patient-focused programs to assist with the management of HE will drive the growth of the global HE therapeutics market during the forecast period.

Late and Inaccurate Diagnosis to Challenge the Market Growth
The symptoms of HE are non-specific. They include personality changes, slurred speech, poor coordination, lethargy, confusion, trembling hands, and bad breath. The symptoms are usually subtle and may be attributed incorrectly to other causes. This can cause delays in diagnosis or inaccurate diagnosis. The absence of an agreed standard procedure or diagnostic test is also a challenge that compounds concerns about the diagnosis of the disease. Hence, the late and inaccurate diagnosis of HE could affect the growth of the global HE therapeutics market during the forecast period.

Download Free sample report for insights on the Drivers, Trends, and Challenges that will help companies evaluate and develop growth strategies for 2021-2025

Our Hepatic Encephalopathy (HE) Therapeutics Market Report Covers the Following Areas:

Hepatic Encephalopathy (HE) Therapeutics Market 2021-2025: Vendor Analysis

The Hepatic Encephalopathy (HE) Therapeutics Market report offers information on several market vendors, including Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc. among others.

Moreover, the market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Download Our FREE Sample Report for more vendor insights with product offerings & news

Hepatic Encephalopathy (HE) Therapeutics Market 2021-2025: Key Highlights

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will assist hepatic encephalopathy (HE) therapeutics market growth during the next five years
  • Estimation of the hepatic encephalopathy (HE) therapeutics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the hepatic encephalopathy (HE) therapeutics market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of hepatic encephalopathy (he) therapeutics market vendors

Related Reports:
Alcoholic Hepatitis Treatment Market by Type and Geography – Forecast and Analysis 2021-2025: The alcoholic hepatitis treatment market size has the potential to grow by USD 695.42 million during 2021-2025, and the market’s accelerated growth momentum will at a CAGR of 6.39%. To get more exclusive research insights: Download Our FREE Sample Report

Global Atherosclerosis Therapeutics Market: The global atherosclerosis therapeutics market size will grow by USD 2.67 billion. This market report provides a detailed analysis of the market by product and geography. To get more exclusive research insights: Download Our FREE Sample Report

Table of Contents:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Size

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 – 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • NADs – Market size and forecast 2020-2025
  • Antibiotics – Market size and forecast 2020-2025
  • Others – Market size and forecast 2020-2025
  • Market opportunity by Product

customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2020-2025
  • Europe – Market size and forecast 2020-2025
  • Asia – Market size and forecast 2020-2025
  • ROW – Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Alfasigma Spa
  • ASKA Pharmaceutical Co. Ltd.
  • Bausch Health Companies Inc.
  • COSMO PHARMACEUTICALS NV
  • Cumberland Pharmaceuticals Inc.
  • Horizon Therapeutics Plc
  • Lupin Ltd.
  • Mallinckrodt Plc
  • Norgin BV
  • Rebiotix Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify existing opportunities in and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio; Technavio

.

Leave a Comment